Seeking Alpha
Research analyst, IPOs, long/short equity
Profile| Send Message|
( followers)  

The following IPOs are expected to price this week:

Applied Optoelectronics (NASDAQ:AAOI), a leading fiber-optic networking products provider, plans to raise $50 million by offering 3.6 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Applied Optoelectronics would command a market value of $182 million. Applied Optoelectronics, which was founded in 1997, booked $69 million in sales over the last 12 months. The Sugar Land, TX-based company plans to list on the NASDAQ under the symbol AAOI. Raymond James and Piper Jaffray are the joint bookrunners on the deal.

Covisint (NASDAQ:COVS), which provides a data sharing platform primarily to the auto and health care industries, plans to raise $64 million by offering 6.4 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Covisint would command a market value of $395 million. Covisint, which was founded in 2000, booked $94 million in sales over the last 12 months. The Detroit, MI-based company plans to list on the NASDAQ under the symbol COVS. Credit Suisse, Pacific Crest and Evercore Partners are the joint bookrunners on the deal.

Enzymotec (NASDAQ:ENZY), which develops lipid-based nutritional ingredients and medical foods, plans to raise $75 million by offering 4.4 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Enzymotec would command a market value of $391 million. Enzymotec, which was founded in 1998, booked $51 million in sales over the last 12 months. The Migdal Ha'Emeq, Israel-based company plans to list on the NASDAQ under the symbol ENZY. BofA Merrill Lynch and Jefferies & Co. are the joint bookrunners on the deal.

Evoke Pharma (NASDAQ:EVOK), which is developing drugs to treat gastrointestinal disorders and diseases, plans to raise $27 million by offering 2.1 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Evoke Pharma would command a market value of $75 million. Evoke Pharma, which was founded in 2007, booked $0 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol EVOK. Aegis Capital is the lead bookrunner on the deal.

Fate Therapeutics (NASDAQ:FATE), an early clinical-stage biotech developing stem cell treatments for orphan diseases, plans to raise $60 million by offering 4.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Fate Therapeutics would command a market value of $219 million. Fate Therapeutics, which was founded in 2007, booked $2 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol FATE. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.

Foundation Medicine (NASDAQ:FMI), which offers diagnostic cancer analyses that provide patient specific data for physicians, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Foundation Medicine would command a market value of $421 million. Foundation Medicine, which was founded in 2009, booked $19 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol FMI. Goldman Sachs and J.P. Morgan are the joint bookrunners on the deal.

Montage Technology Group (NASDAQ:MONT), a China-based fabless provider of chips for set-top boxes and memory computing, plans to raise $92 million by offering 7.1 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Montage Technology Group would command a market value of $364 million. Montage Technology Group, which was founded in 2004, booked $90 million in sales over the last 12 months. The Shanghai, China-based company plans to list on the NASDAQ under the symbol MONT. Deutsche Bank, Barclays and Stifel are the joint bookrunners on the deal.

Ophthotech (NASDAQ:OPHT), a clinical-stage biotech developing novel therapeutics for eye diseases, plans to raise $100 million by offering 5.7 million shares at a price range of $16.00 to $19.00. At the midpoint of the proposed range, Ophthotech would command a market value of $494 million. Ophthotech, which was founded in 2007, booked $0 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol OPHT. Morgan Stanley and J.P. Morgan are the joint bookrunners on the deal.

Pattern Energy Group (NASDAQ:PEGI), which owns and operates eight wind power projects in the US, Canada and Chile, plans to raise $320 million by offering 16.0 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Pattern Energy Group would command a market value of $1.0 billion. Pattern Energy Group, which was founded in 2009, booked $154 million in sales over the last 12 months. The San Francisco, CA-based company plans to list on the NASDAQ under the symbol PEGI. BMO Capital Markets, RBC Capital Markets and Morgan Stanley are the joint bookrunners on the deal. (Please note: Dual listing on the NASDAQ and the Toronto Stock Exchange.)

Premier (NASDAQ:PINC), a member-owned healthcare alliance offering supply chain and performance services, plans to raise $690 million by offering 28.2 million shares at a price range of $23.00 to $26.00. At the midpoint of the proposed range, Premier would command a market value of $3.4 billion. Premier, which was founded in 1996, booked $869 million in sales over the last 12 months. The Charlotte, NC-based company plans to list on the NASDAQ under the symbol PINC. J.P. Morgan, BofA Merrill Lynch and Wells Fargo Securities are the joint bookrunners on the deal.

RingCentral (NYSE:RNG), which provides cloud-based phone systems to small businesses, plans to raise $90 million by offering 7.5 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, RingCentral would command a market value of $808 million. RingCentral, which was founded in 1999, booked $136 million in sales over the last 12 months. The San Mateo, CA-based company plans to list on the NYSE under the symbol RNG. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal.

Tecogen (NASDAQ:TGEN), which sells and services commercial natural gas-powered cogeneration systems, plans to raise $20 million by offering 3.0 million shares at a price range of $5.50 to $7.50. At the midpoint of the proposed range, Tecogen would command a market value of $113 million. Tecogen, which was founded in 2000, booked $15 million in sales over the last 12 months. The Waltham, MA-based company plans to list on the NASDAQ under the symbol TGEN. Northland Securities and Scarsdale Equities are the joint bookrunners on the deal.

Violin Memory (NYSE:VMEM), which manufactures enterprise flash-based storage arrays, plans to raise $162 million by offering 18.0 million shares at a price range of $8.00 to $10.00. At the midpoint of the proposed range, Violin Memory would command a market value of $874 million. Violin Memory, which was founded in 2005, booked $95 million in sales over the last 12 months. The Mountain View, CA-based company plans to list on the NYSE under the symbol VMEM. J.P. Morgan, Deutsche Bank, BofA Merrill Lynch and Barclays are the joint bookrunners on the deal.

Source: 13 U.S. IPOs Planned For The Week Of September 23